Back to search results

Radiation Therapy for Solid Tumors That Have Spread to Soft Tissue

This study is looking at two types of radiation therapy for solid tumors that have spread to soft tissue. It compares lattice radiation therapy (LRT) with standard stereotactic body radiation therapy (SBRT). The study wants to see which one is more effective and how they affect the body's immune cells that fight cancer. You might be able to join if you are 18 or older and have certain advanced or metastatic solid tumors, including breast cancer (invasive ductal or lobular) or non-small cell lung cancer. The main goal is to measure how many patients respond to the treatment after 12 weeks. The current recruitment status is unclear.

Study design
This interventional study plans to enroll 26 participants. It compares two different radiation therapy techniques.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 12 weeks from baseline.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05837767

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

Recruiting
NAAges 18+InterventionalTreatment
Memorial Sloan Kettering Cancer Center
~26 participants
Updated 2026-03-30 on ClinicalTrials.gov
What's tested:Palliative radiotherapy

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall Response Rate (ORR)
Measured over 12 weeks from baseline

Conditions

Invasive Ductal Breast Carcinoma
Invasive Ductal Breast Carcinoma Stage IV
Lobular Breast Carcinoma
Lobular Breast Carcinoma Stage IV
Non Small Cell Lung Cancer
NSCLC
Gastrointestinal Cancer
Gastrointestinal Squamous Cell Cancer
Gastrointestinal Adenocarcinoma
Pancreatic Cancer
Bladder Cancer
Renal Cell Carcinoma
Melanoma
Sarcoma
Metastatic Solid Tumor

Explore related trials

Bladder CarcinomaBreast CarcinomaLung Non-Small Cell CarcinomaMalignant Digestive System NeoplasmMelanomaPancreatic CarcinomaRenal Cell CarcinomaSarcomaSolid Neoplasm

Where it's being run

7 sites across 2 states
New York4
New Jersey3

Study leadership

  • Atif Khan, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Atif Khan, MD
[email protected]
848-225-6334
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with biopsy confirmed advanced/metastatic solid tumors of the following types: invasive ductal or lobular breast carcinoma (all histological and intrinsic subtypes), non-small cell lung cancer (NSCLC, all subtypes), gastrointestinal squamous cell or adenocarcinomas (including pancreatic cancer), bladder cancer, renal cell carcinoma, melanoma, and soft tissue sarcoma (all subtypes), who require and are being planned for palliative radiation therapy to at least one site of extracranial metastatic disease measuring at least 5 cm in a single axis. If a patient, requires palliative radiotherapy to additional sites, these can be treated with standard of care SBRT per departmental guidelines.
Age ≥ 18 years
ECOG Performance Status of 0 or 1.

Exclusion

Patients who are pregnant or breastfeeding
Prior radiation therapy to the candidate metastatic sites under consideration for treatment ("re-irradiation" is disallowed).
Medical condition such as uncontrolled infection (including HIV), uncontrolled diabetes mellitus, or connective tissue diseases (lupus, systemic sclerosis, or other collagen vascular diseases) that, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient.
Patients with a "currently active" metastatic second malignancy.
Patients on oral or parental corticosteroids. Physiological doses of steroids are permitted (eg for patients with adrenal insufficiency). If patients are on supraphysiological doses of steroids, these must be discontinued and held during the period of the study.
Concomitant anti-neoplastic treatment is not allowed during the days of radiation treatment delivery and should be completed or held for 3 days prior to commencement of protocol treatment and for 3 days following completion of radiotherapy, or with resolution of associated acute toxicities.
Unwilling or unable to participate in all required study evaluations and procedures.
Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local patient privacy regulations).

What this trial measures

  • Overall Response Rate (ORR)12 weeks from baseline

    The primary endpoint is ORR in the LRT-treated lesion, as defined by RECIST v.1.1 criteria, at 12 weeks on a standard-of-care response assessment CT or F-18-FDG PET/CT scan after LRT.